Document is current
Any future updates will be listed below
-
Authors
Sabé, Michel https://orcid.org/0000-0002-8530-5596
Sulstarova, Adi
Glangetas, Alban
De Pieri, Marco
Mallet, Luc
Curtis, Logos https://orcid.org/0000-0003-1020-9425
Richard-Lepouriel, Héléne https://orcid.org/0000-0002-0778-3728
Penzenstadler, Louise
Seragnoli, Federico
Thorens, Gabriel
Zullino, Daniele
Preller, Katrin https://orcid.org/0000-0003-0413-7672
Böge, Kerem
Leucht, Stefan
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Kaiser, Stefan
Kirschner, Matthias https://orcid.org/0000-0002-9486-1439
- License Information
-
More Information
Article History
Received: 1 February 2024
Revised: 9 October 2024
Accepted: 17 October 2024
First Online: 27 November 2024
Competing interests
: CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. KHP is currently an employee of Boehringer Ingelheim GmBH & CO KG, Chief Scientist and on the Board of Directors of the Heffter Research Institute, and scientific advisor for the MIND Foundation. MaS has received honoraria/has been a consultant for AbbVie, Angelini, Lundbeck and Otsuka. SK has received advisory board honoraria from Boehringer Ingelheim and royalties for cognitive testing and training software from Schufried. All other authors report no conflicts of interest.
